Atea Pharmaceuticals, Inc.

Good afternoon, everyone, and welcome to the ATF Pharmaceuticals 3rd Quarter 2025 Financial Results and Business Update Conference Call. At this time, all participants are in listen-only mode. Following the formal remarks, we'll open the call up for your questions. I would now like to turn the call over to Jonay Barnes, Senior Vice President of Investor Relations and Corporate Communication at ATF Pharmaceuticals. Ms. Barnes, please proceed.

Thank you, Operator. Good afternoon, everyone, and welcome to Atea Pharmaceutical's third quarter 2025 financial results and business update conference call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at ir.ateafarma.com. With me from Atea are our Chief Executive Officer and Founder, Dr. John-Pierre Sommadosi, Chief Development Officer, Dr. Janet Hammond, Chief Medical Officer, Dr. Arantja Horga, Chief Commercial Officer, John Vavrica, and Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran, all of whom will be available for the Q&A portion of today's call. Before we begin the call, and as outlined on slide two, I would like to remind you that today's discussion will contain forward-looking statements that involve risk and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean-Pierre.

Thank you, Janae. Good afternoon, everyone, and thank you for joining us. I will begin our slides today. I'm pleased to share with you the significant progress and achievements we have made this quarter, which is a testament to strong execution across our team. Our global phase three program for the treatment of HCV is on track, and we expect to complete patient enrollment for our North American trial, CBR, next month. This timeline leads us to the first phase three top line result in mid-2026. For C-Forward, our trial outside of North America, we anticipate enrollment completion mid-2026 with top-line results anticipated by late-2026. And our answer will provide an update on our Phase III program. A few days ago, new modeling data was presented at the LIBER meeting 2025 in Washington, D.C., along with two additional data sets further demonstrating the antiviral potency with short treatment duration of our regimen for the treatment of hepatitis C. Janet will review the highlight of this data next. I'm pleased also to report that we announced today new exciting research findings. including evidence of a unique dual mechanism faction for benifazovir against HCV, further demonstrating its differentiation and potency, and I will review this data in a moment. In addition, I'm also very pleased to share with you that we are expanding our antiviral hepatitis pipeline for a major unmet medical need of immunocompromised patients living with hepatitis E infection. We have identified two new potent candidates derived from our nucleotide platform. IND enabling studies are ongoing to select the clinical candidate, which phase one initiation anticipated in mid-2026. We will discuss this program in more detail today's presentation. At the end of the third quarter, we maintain a strong balance sheet with approximately $329.3 million in cash, cash equivalent, and marketable securities, providing runway through 2027. This strong cash position enables us to fully fund our Phase III program launched the new regimen, and advanced our new HCV development program. With that, I will now turn the call over to Janet to review the highlights of the presentation at the LIVER meeting. Janet?